Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors

Annals of Oncology

Volumn 26, Issue 11, 2015, Pages 2305-2310

  Boer, H ^a   Proost, J H ^a   Nuver, J ^a   Bunskoek, S ^a   Gietema, J Q ^a   Geubels, B M ^a   Altena, R ^a   Zwart, N ^a   Oosting, S F ^a   Vonk, J M ^a   Lefrandt, J D ^a   Uges, D R A ^a   Meijer, C ^a   de Vries, E G E ^a   Gietema, Jourik A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

00 2177; 04 3157; 09 4365; BEP the dutch cancer society; Germ cell cancer; long term toxicity; nephrotoxicity; platinum

Indexed keywords

CISPLATIN; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLATINUM;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVOR; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGONADISM; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; TESTIS CANCER; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; FOLLOW UP; MIDDLE AGED; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CISPLATIN; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PLATINUM; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947757133     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv369     Document Type: Article

References (21)

1. Haugnes HS, Bosl GJ, Boer H et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30: 3752-3763.
2. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
3. Haugnes HS, Aass N, Fosså SD et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
4. de Haas EC, Altena R, Boezen HM et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013; 24: 749-755.
5. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355: 1075-1076.
6. Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008; 8: 7.
7. Sprauten M, Darrah TH, Peterson DR et al. Impact of long-term serum platinum concentrations on neuro-and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30: 300-307.
8. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-e161.
9. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
10. Feng Y, Pollock BG, Ferrell RE et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006; 61: 558-569.
11. Fosså SD, Aass N, Winderen M et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002; 13: 222-228.
12. Lauritsen J, Mortensen MS, Kier MG et al. Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol 2015; 26: 173-178.
13. Krarup-Hansen A, Rietz B, Krarup C et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 1999; 25: 29-40.
14. Berger CC, Bokemeyer C, Schneider M et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A: 2229-2238.
15. Huddart RA, Norman A, Moynihan C et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005; 93: 200-207.
16. Nord C, Bjøro T, Ellingsen D et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003; 44: 322-328.
17. Dikhoff TGMH, De Goeij JJM, McVie JG. Long-term body retention and tissue distribution of platinum in cisplatin treated cancer patients. J Radioanal Nucl Chem 1998; 236: 81-86.
18. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701-706.
19. Vaughn DJ, Palmer SC, Carver JR et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112: 1949-1953.
20. Nuver J, De Haas EC, Van Zweeden M et al. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23: 247-253.
21. Fung C, Fosså SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2013; 31: 3807-3814.